Efficacy of ezetimibe for the treatment of non‐alcoholic steatohepatitis: An open‐label, pilot study

Aim:  Non‐alcoholic steatohepatitis (NASH) is considered a hepatic manifestation of metabolic syndrome. However, effective drug therapy for NASH has not been established yet. In the present study, we evaluated the efficacy of 6 months of ezetimibe treatment for NASH patients with dyslipidemia for the comparison of improvement of the clinical parameters and histological alterations.

[1]  Hirokazu Takahashi,et al.  Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease. , 2009, Journal of hepatology.

[2]  M. Haraguchi,et al.  Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome , 2007, FEBS letters.

[3]  Hirokazu Takahashi,et al.  High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH , 2007, Journal of Gastroenterology.

[4]  M. Willingham,et al.  Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. , 2007, The Journal of clinical investigation.

[5]  J. Dietschy,et al.  Lysosomal unesterified cholesterol content correlates with liver cell death in murine Niemann-Pick type C disease Published, JLR Papers in Press, January 14, 2007. , 2007, Journal of Lipid Research.

[6]  R. Hegele,et al.  NPC1L1: Evolution From Pharmacological Target to Physiological Sterol Transporter , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[7]  R. Sterling,et al.  Review article: drug therapy for non‐alcoholic fatty liver disease , 2006, Alimentary pharmacology & therapeutics.

[8]  N. Yoshiike,et al.  Epidemiological aspects of obesity and NASH/NAFLD in Japan. , 2005, Hepatology research : the official journal of the Japan Society of Hepatology.

[9]  T. Saibara.  Nonalcoholic steatohepatitis in Asia-Oceania. , 2005, Hepatology Research.

[10]  B. Hawes,et al.  The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[11]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[12]  Y. Tokusashi,et al.  Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis , 2004, Hepatology.

[13]  J. Hui,et al.  Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them , 2003, Journal of Gastroenterology and Hepatology.

[14]  G. Marchesini,et al.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome , 2003, Hepatology.

[15]  A. Sanyal,et al.  AGA technical review on nonalcoholic fatty liver disease. , 2002, Gastroenterology.

[16]  Laura Liscum,et al.  Niemann-Pick C1 , 2002, Current Biology.

[17]  R. Karim,et al.  NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome , 2002, Hepatology.

[18]  J. Horton.  Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis. , 2001, Biochemical Society transactions.

[19]  H. Davis,et al.  Ezetimibe, a Potent Cholesterol Absorption Inhibitor, Inhibits the Development of Atherosclerosis in ApoE Knockout Mice , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[20]  G. Marchesini,et al.  Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. , 2001, Diabetes.

[21]  H. Bloch.  What is the target? , 2000, Child development.

[22]  G. Brandi,et al.  Prevalence of and Risk Factors for Hepatic Steatosis in Northern Italy , 2000, Annals of Internal Medicine.

[23]  S. Yamashita,et al.  Abdominal fat: standardized technique for measurement at CT. , 1999, Radiology.

[24]  M. Brown,et al.  Independent regulation of sterol regulatory element-binding proteins 1 and 2 in hamster liver. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Hanson,et al.  The natural history of nonalcoholic steatohepatitis: A follow‐up study of forty‐two patients for up to 21 years , 1990, Hepatology.

[26]  K. Ishak,et al.  Alcohollike liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. , 1988, Gastroenterology.

[27]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[28]  E. Hughes,et al.  Unexpected beneficial effect in the use of ezetimibe in non-alcoholic fatty liver disease. , 2006, Medical hypotheses.

[29]  H. Davis,et al.  The target of ezetimibe is Niemann – Pick C 1-Like 1 ( NPC 1 L 1 ) , 2005 .

[30]  E. Brunt.  Nonalcoholic Steatohepatitis: Definition and Pathology , 2001, Seminars in liver disease.

[31]  S.,et al.  Abdominal fat. , 1999, Harvard women's health watch.

[32]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[33]  S. Grundy.  Absorption and metabolism of dietary cholesterol. , 1983, Annual review of nutrition.

[34]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.

[35]  Luquan Wang,et al.  Materials and Methods Figs. S1 to S4 Tables S1 and S2 References Niemann-pick C1 like 1 Protein Is Critical for Intestinal Cholesterol Absorption , 2022 .